AzTrials
AzTrials

Adenomyosis of UterusAdenomyosisNCT07478614

Multicenter Observational Cohort Study on the Epidemiology of Therapeutic Strategies in Patients Affected by Adenomyosis

An observational study of Adenomyosis of Uterus and Uterine Diseases, run by SCHETTINI SERGIO at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The primary objective of this multicenter observational cohort study is to evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence. Read more about this study

Who is it for?
Ages 20 to 50 years, women only
What is being tested?
This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.
How many people
200 participants
Where
1 siteItaly
Study dates
1 Jun 2025to 1 Feb 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Women only
  • Adult

Study population: Female patients aged between 20 and 50 years, symptomatic for adenomyosis, with a confirmed diagnosis.

Who may be able to join

  • Age between 20 and 50 years; Instrumental (ultrasound or MRI) and/or histological diagnosis of adenomyosis; Adenomyosis-associated pain with a VAS score ≥ 4 and/or presence of heavy menstrual bleeding (HMB) defined as a score > 100 on the Pictorial Blood Assessment Chart (PBAC); Provision of written informed consent to participate in the study; Willingness to be followed at the participating center for the entire duration of the study.

Who cannot join

  • Current or previous clinical and/or instrumental diagnosis of endometriosis; Suspected or confirmed pregnancy; Inability to understand the purpose of the study and to provide informed consent.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sergio Schettini contact

+39 335424088

schettini@icloud.com

Italy1 site, 1 recruiting
  • Ospedale San Carlo

    Potenza

    Sergio Schettini, +39 335424088, schettini@icloud.com

    Maria Laura Pisaturo, 3384369617, marialaura.pisaturo@icloud.com

    Recruiting

Other trials in Italy

About this study

The primary objective of this multicenter observational cohort study is to evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence. The secondary objective is to identify the criteria guiding therapeutic choices in daily clinical practice within a multicenter setting.

Adenomyosis is a benign gynecological condition characterized by the presence of endometrial-like epithelial and stromal tissue within the myometrium. It mainly affects women aged 41 to 45 years and typically presents with symptoms such as chronic pelvic pain, dysmenorrhea, and menorrhagia. The most commonly used treatments include GnRH agonists, progestins, and intrauterine devices (IUDs); however, there are no universally accepted guidelines for the management of this condition, and therapeutic options remain a matter of debate.

Read more

This is a multicenter observational cohort study with both prospective and retrospective recruitment of women affected by adenomyosis. Italian clinical centers will be included and will recruit patients aged between 20 and 50 years, with a diagnosis of adenomyosis confirmed by ultrasound or magnetic resonance imaging (MRI) and/or histology, and presenting significant symptoms (VAS ≥ 4 for pelvic pain or bleeding > 100 on the Pictorial Blood Assessment Chart - PBAC). Cases of concomitant endometriosis, pregnancy, and conditions preventing informed consent will be excluded.

Each center will collect data regarding the prescribed treatment, its effectiveness, and treatment persistence over time. The study duration will be 12 months, with data collection at baseline (V0), 3 months (V1), 6 months (V2), and 12 months (V3). Approximately 200 patients will be enrolled across 20 centers, with an enrollment period of 12 months.

The analysis will be conducted based on the frequency of treatment use and changes in treatment response in relation to age, symptoms, and other clinical factors.

Data Collection Methodology

Patients will undergo regular clinical evaluations at 3 months, 6 months, and 12 months. Data will be collected using validated questionnaires (VAS, PBAC, SF-12). Transvaginal ultrasound examinations will be performed, and ferritin and hemoglobin levels will be measured. Treatment adherence and tolerability will be monitored through interviews and the recording of adverse events (AEs), including serious adverse events (SAEs).

Data Analysis

The analysis will be descriptive, focusing on the frequency of prescribed treatments and patient characteristics (age, symptoms, comorbidities). Continuous variables will be analyzed using mean and standard deviation (for normally distributed data) or median and range (for non-normally distributed data), while categorical variables will be analyzed using proportions and 95% confidence intervals. Differences between groups will be explored using appropriate statistical tests.

Expected Results and Implications

This study will provide crucial information on the epidemiology of therapeutic approaches to adenomyosis in Italy, helping to bridge existing knowledge gaps and supporting the development of evidence-based recommendations for clinical management. The results will help guide medical practice, improve patients' quality of life, and contribute to the development of therapeutic guidelines.

Dissemination of Results

The study results will be published in scientific articles in international peer-reviewed journals, with active participation of the physicians involved in the research.

Being tested
This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.
Medical subject headings
Adenomyosis, Uterine Diseases, Genital Diseases, Female, Menorrhagia, Dysmenorrhea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.Other

    This is a non-interventional study. Treatment allocation will not be influenced by the study protocol.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Epidemiology of Therapeutic Strategies in Patients with Adenomyosis

    To evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence.

    Measured: Outcomes will be recorded at treatment initiation (baseline) and at 3, 6, and 12 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Mar 2026
  2. Study start1 Jun 2025
  3. Primary completion18 Feb 2026
  4. Study completion1 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07478614
Sponsor's protocol ID
20240046096
Acronym
Adenomyosis
Status last verified
Feb 2026
First submitted
18 Feb 2026
Last updated
17 Mar 2026
Results posted
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in